Network meta-analysis compares 20 blood biomarkers for pancreatic cancer

A network meta-analysis of 185 studies compared the diagnostic performance of 20 blood-based biomarkers for pancreatic cancer, identifying IMP3, S100P and CA195 as the leading candidates under a Bayesian analysis. The systematic review focused on sensitivity, specificity and an overall ranking measure, with results interpreted as comparative evidence rather than proof of clinical readiness.

Researchers searched PubMed, Embase, Web of Science and the Cochrane Library for studies evaluating blood-based biomarkers in pancreatic cancer diagnosis. They selected the 20 most commonly reported biomarkers and extracted sensitivity, specificity and other diagnostic information from 185 eligible studies. The review then used a Bayesian analysis-of-variance model to pool and compare the biomarkers’ diagnostic measures.

The statistical model generated both overall rankings and separate assessments of sensitivity and specificity. IMP3, S100P and CA195 occupied the top three positions when the researchers calculated the dominant index. IMP3 also appeared among the strongest performers for specificity, while S100P received the highest sensitivity ranking in the frequentist analysis.

The frequentist analysis, which used SUCRA to summarize the ranking of each biomarker, produced a different leading group for sensitivity. S100P ranked first, followed by Span-1 and MIC-1. For specificity, p53 ranked first, with IMP3 and CA72-4 completing the top three. The variation across ranking methods shows why the results should be understood as a comparative summary rather than a single definitive test order.

The study conducted subgroup analyses across different study designs, control groups and geographic regions. The authors reported that the results in these analyses were consistent with the overall findings. The review did not establish that any biomarker should replace CA19-9 in routine practice, and the authors said that IMP3 and S100P warrant further investigation in prospective studies to confirm their clinical utility.

CA19-9 remains the most widely used serum biomarker for pancreatic cancer, but the review noted that its sensitivity and specificity are suboptimal, limiting its clinical utility. The authors also emphasized that the analysis compares published diagnostic performance across multiple biomarkers. As a result, the ranked findings identify markers for additional evaluation but do not by themselves demonstrate improved patient outcomes or a complete clinical testing strategy.

Overall, the review points to IMP3 and S100P as promising blood-based markers with high diagnostic accuracy in the comparative analysis. CA195 also ranked strongly in the Bayesian assessment, while p53, Span-1, MIC-1 and CA72-4 led particular frequentist rankings. These findings support prospective investigation of the most consistently performing candidates, while the need for clinical confirmation remains central to the study’s conclusion.

Subject of Research: Comparative diagnostic accuracy of blood-based biomarkers for pancreatic cancer

Article Title: Comparative diagnostic accuracy of twenty blood-based biomarkers for pancreatic cancer: a network meta-analysis

Article References: Lu, T.-L., Gao, J., Liu, R.-H., & Chen, C.-W. (2026). Comparative diagnostic accuracy of twenty blood-based biomarkers for pancreatic cancer: a network meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17140-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17140-6

Keywords: pancreatic cancer, blood biomarkers, network meta-analysis, diagnostic accuracy, IMP3, S100P, CA195, CA19-9, sensitivity, specificity, systematic review, Comparative